Quantcast

Latest Alkynes Stories

2014-05-20 12:33:19

Oncoprex Combined with Tarceva for Patients With and Without EGFR Mutations AUSTIN, Texas, May 20, 2014 /PRNewswire/ -- Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. Oncoprex is a targeted biologic incorporating the pan-kinase inhibitor TUSC2, which inhibits oncogenic kinases via multiple pathways. The trial is...

2014-04-28 23:03:51

The ArTorch® Precision Flame Tool website offers a detailed look at the ArTorch® product line. Fort Lauderdale, Florida (PRWEB) April 28, 2014 Uniweld Products is proud to announce the completion and launch of their ArTorch® Pinpoint Flame Tool Website. ArTorch® Pinpoint Flame Tools are available by individual parts or as a complete outfit. Visit artorch.com and check out the variety of available tools sets and additional ArTorch® accessories for precision optical...

2014-04-24 12:30:28

The Majority of Non-Prescribers Anticipate Prescribing Gilotrif Within the Next Three Months, According to Findings from Decision Resources Group BURLINGTON, Mass., April 24, 2014 /PRNewswire/ -- Decision Resources Group finds that at six months post-launch in the United States, 49 percent of surveyed U.S. medical oncologists have prescribed Boehringer Ingelheim's irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Gilotrif, for NSCLC patients outside of...

2014-04-07 12:33:26

New data demonstrates VAL-083 is superior to standard platinum-based chemotherapy in an established in vivo model of non-small cell lung cancer (NSCLC) VANCOUVER, British Columbia, MENLO PARK, Calif. and SAN DIEGO, April 7, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014...

Carbon Nanotubes Grow In Combustion Flames
2014-04-02 15:36:48

Institute of Transformative Bio-Molecules (ITbM), Nagoya University Professor Stephan Irle of the Institute of Transformative Bio-Molecules (WPI-ITbM) at Nagoya University and co-workers at Kyoto University, Oak Ridge National Lab (ORNL), and Chinese research institutions have revealed through theoretical simulations that the molecular mechanism of carbon nanotube (CNT) growth and hydrocarbon combustion actually share many similarities. In studies using acetylene molecules (ethyne; C2H2,...

2014-03-27 23:01:09

Kristine K. Kraft, Plaintiffs' Liaison Counsel and Co-Lead Counsel in the NuvaRing® MDL, provides an update on the NuvaRing® Multidistrict Litigation (MDL 2385), particularly that the deadline for the submission of eligible claimants’ opt-in forms has been extended until April 9, 2014. St. Louis, Missouri (PRWEB) March 27, 2014 A $100 Million settlement was approved by United States District Court Judge Rodney W. Sippel in the NuvaRing® Multidistrict Litigation In re:...

2014-03-26 11:23:23

Presentations at the 4th European Lung Cancer Conference A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumor cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress. For decades, scientists and doctors thought immunotherapy –treatments that harness the immune system to fight a disease-- was of marginal benefit in lung cancer, says Jean-Charles Soria, Institute Gustave Roussy in Paris, France. However a...

2014-03-13 23:26:38

Kristine K. Kraft, Plaintiffs' Liaison Counsel and Co-Lead Counsel in the NuvaRing® MDL, provides an update on the NuvaRing® Multidistrict Litigation (MDL 2385), particularly that the deadline for the submission of eligible claimants’ opt-in forms has now been extended until March 25, 2014. St. Louis, MO (PRWEB) March 13, 2014 On February 7, 2014, United States District Court Judge Rodney W. Sippel approved a $100 Million settlement in the NuvaRing® Multidistrict...

New Combo Therapy Shows Promise For Cervical Cancer Treatment
2014-03-10 12:12:44

Bret Smith for redOrbit.com - Your Universe Online A team of Brazilian scientists has identified a promising new combination treatment that targets cervical cancer, according to a new report published in the journal Cancer. Patients with locally-advanced cervical cancer are typically prescribed cisplatin-based chemoradiation therapy (CRT), yet the benefits of this treatment have largely gone unresearched since the late 1990s, the study authors claimed. In search of a new treatment...

2014-02-09 23:01:36

Roger Denton, Plaintiffs' Lead Counsel and one of the lead negotiators for the plaintiffs in the NuvaRing® MDL, reports that a $100 Million settlement has been reached with Merck to settle all NuvaRing® cases nationwide. St. Louis, MO (PRWEB) February 09, 2014 On February 7, 2014, United States District Court Judge Rodney W. Sippel approved a $100 Million settlement in the NuvaRing® Multidistrict Litigation In re: NuvaRing® Products Liability Litigation (MDL No....


Word of the Day
ambsace
  • Bad luck; misfortune.
  • The smallest amount possible or the most worthless thing.
The word 'ambsace' comes from a Latin word meaning 'both'.